Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Tax Provisions (2016 - 2025)

Amicus Therapeutics (FOLD) has disclosed Tax Provisions for 14 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Tax Provisions rose 121.35% year-over-year to $1.5 million, compared with a TTM value of $27.3 million through Dec 2025, changed 0.18%, and an annual FY2025 reading of $27.3 million, changed 0.18% over the prior year.
  • Tax Provisions was $1.5 million for Q4 2025 at Amicus Therapeutics, down from $17.0 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $17.0 million in Q3 2025 and bottomed at -$14.2 million in Q4 2022.
  • Average Tax Provisions over 5 years is $3.0 million, with a median of $2.8 million recorded in 2021.
  • Peak annual rise in Tax Provisions hit 2310.44% in 2022, while the deepest fall reached 576.82% in 2022.
  • Year by year, Tax Provisions stood at $3.0 million in 2021, then crashed by 576.82% to -$14.2 million in 2022, then skyrocketed by 115.36% to $2.2 million in 2023, then crashed by 411.73% to -$6.8 million in 2024, then soared by 121.35% to $1.5 million in 2025.
  • Business Quant data shows Tax Provisions for FOLD at $1.5 million in Q4 2025, $17.0 million in Q3 2025, and $5.2 million in Q2 2025.